News | May 20, 2008

Remote Interrogation Detects Events Earlier in Pacemaker Patients

May 21, 2008 - Physicians can detect and diagnose clinically actionable events earlier in pacemaker patients who utilize remote interrogation compared to those that are followed via routine office visits augmented by transtelephonic monitoring (TTM), according to the PREFER Trial, a late-breaking clinical trial presented at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions.

The PREFER Trial is the first to compare remote monitoring diagnosis rates to diagnosis rates using traditional pacemaker follow-up. The prospective, randomized trial analyzed data from 897 patients from 50 centers throughout the United States. At enrollment, patients were randomized 2:1 to have pacemaker follow-up by a combination of in-person programming evaluations augmented by either remote interrogation or transtelephonic rhythm strip evaluations. At each follow-up visit or scheduled transmission, physicians reviewed the available data for pre-specified clinically actionable events.

“With current pacemaker systems continuously recording clinical information, clinicians now have robust and objective data to diagnose clinical events. However, this information is only valuable if providers can access it in a timely manner that enables clinical intervention before the event progresses,” said lead author Bruce L. Wilkoff, MD, FHRS, Director of Cardiac Pacing and Tachyarrhythmia Devices at the Cleveland Clinic and chair of the Heart Rhythm Society’s Health Policy Committee. “Internet-based remote monitoring tools now make it possible for clinical information to reach physicians with minimal intrusiveness for both the patient and the clinician.”

At the end of the 12 month trial, results showed that clinically actionable events are detected earlier in patients that used remote interrogation instead of TTM monitoring. Overall, less than 2 percent of events were detected by remote transmission in patients using TTM monitoring, while more than 60 percent were detected in the patient group that used remote interrogation.

For more information: www.hrsonline.org


Related Content

News | Pacemakers

March 26, 2024 — UC San Diego Health is the first health system in San Diego to successfully implant the world’s first ...

Home March 26, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, BIOTRONIK proudly announces the world ...

Home March 15, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, Biotronik announces the world’s first ...

Home March 15, 2024
Home
News | Pacemakers

January 5, 2024 — Medtronic, a global leader in healthcare technology, today announced it has received CE (Conformité ...

Home January 05, 2024
Home
News | Pacemakers

August 21, 2023 — The first implant in Europe of Biotronik’s latest pacemaker and CRT-P generation was conducted in ...

Home August 21, 2023
Home
News | Pacemakers

July 6, 2023 — BIOTRONIK announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge ...

Home July 06, 2023
Home
News | Pacemakers

July 5, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR dual chamber (DR ...

Home July 05, 2023
Home
News | Pacemakers

June 1, 2023 — Every year more than one million people receive a pacemaker. Until now, leadless versions were only ...

Home June 01, 2023
Home
News | Pacemakers

May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device ...

Home May 25, 2023
Home
News | Pacemakers

May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted ...

Home May 12, 2023
Home
Subscribe Now